title: Anti-TNF in rheumatoid arthritis: an overview.
abstract: Since the introduction of tumor necrosis factor (TNF)-α inhibitors, the treatment of rheumatoid arthritis (RA) has been revolutionized. The approach of targeting TNF-α has considerably improved the success in the treatment of RA. Over the last 3 decades five different TNF-α inhibitors have been administered: infliximab, etanercept, adalimumab, golimumab, and certolizumab-pegol. All of them show excellent efficacy with similar rates of clinical response and prevention of radiographic disease progression. With improved therapies, treatment strategies have also changed, with the aims now being to achieve and maintain remission. Most recently, the discussion expands to the issue of treatment reduction in patients who have achieved sustained remission; here, the discontinuation of TNF-α inhibitor therapy has become an area of interest, given obvious economic and risk-benefit evaluations. However, only little is known if "biologic free" remission is possible in patients with sustained remission following intensive TNF-α inhibitor therapy.
authors: Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria, helga.radner@meduniwien.ac.at.
authors: Helga
authors: H
authors: Radner
authors: Daniel
authors: D
authors: Aletaha
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha
references: Ann Rheum Dis. 2013 Jan;72 (1):64-71
references: 22562973
references: Arthritis Rheum. 2010 Jan;62(1):22-32
references: 20039405
references: N Engl J Med. 2000 Nov 30;343 (22):1594-602
references: 11096166
references: Ann Rheum Dis. 1988 Sep;47(9):768-72
references: 3263088
references: Int Immunol. 2012 May;24(5):275-81
references: 22457216
references: J Rheumatol Suppl. 2007 Nov;80:25-33
references: 17985420
references: Arthritis Rheum. 2006 Jan;54(1):26-37
references: 16385520
references: Semin Arthritis Rheum. 2000 Apr;29(5):305-20
references: 10805355
references: Arthritis Rheum. 2004 Jul;50(7):2327-37
references: 15248234
references: Ann Rheum Dis. 2013 Oct;72(10):1613-20
references: 23687260
references: J Biol Chem. 2000 Feb 18;275(7):4858-64
references: 10671521
references: Arthritis Rheum. 2009 Aug;60(8):2272-83
references: 19644849
references: Joint Bone Spine. 2008 Jul;75(4):408-15
references: 18455949
references: Arthritis Rheum. 2008 Nov;58(11):3319-29
references: 18975346
references: Ann Rheum Dis. 2009 Jun;68(6):805-11
references: 19015206
references: N Engl J Med. 1997 Jul 17;337(3):141-7
references: 9219699
references: Arthritis Rheum. 2008 Jul;58(7):1921-30
references: 18576334
references: Ann Rheum Dis. 2009 Jun;68(6):797-804
references: 19015207
references: J Exp Med. 2002 Jul 1;196(1):77-85
references: 12093872
references: Arthritis Res Ther. 2011 Feb 16;13(1):R25
references: 21324169
references: Curr Opin Rheumatol. 2009 May;21(3):211-5
references: 19399992
references: Rheum Dis Clin North Am. 1990 Aug;16(3):513-37
references: 2217956
references: BioDrugs. 2014 Apr;28 Suppl 1:S15-23
references: 24687235
references: Joint Bone Spine. 2009 Jul;76(4):350-5
references: 19362504
references: Lancet. 2013 May 4;381(9877):1541-50
references: 23515142
references: Ann Rheum Dis. 2014 Jan;73(1):86-94
references: 23962455
references: Lancet. 2007 Dec 1;370(9602):1861-74
references: 17570481
references: Nat Med. 2003 Oct;9(10):1245-50
references: 14520364
references: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD007848
references: 19821440
references: Arthritis Rheum. 2006 Sep;54(9):2793-806
references: 16947627
references: Arthritis Rheum. 2004 May;50(5):1400-11
references: 15146409
references: Ann Rheum Dis. 2014 Mar;73(3):492-509
references: 24161836
references: Ann Rheum Dis. 2010 Apr;69(4):631-7
references: 20215140
references: Ann Rheum Dis. 2010 Jun;69(6):1129-35
references: 20444749
references: Lancet. 2004 Feb 28;363(9410):675-81
references: 15001324
references: Arthritis Rheum. 2004 Apr;50(4):1051-65
references: 15077287
references: Ann Rheum Dis. 2015 Feb;74(2):389-95
references: 24288014
references: Ann Rheum Dis. 2008 Nov;67(11):1516-23
references: 18625622
references: Ann Rheum Dis. 2009 Jul;68(7):1153-8
references: 18930988
references: PLoS One. 2012;7(1):e30275
references: 22272322
references: Lancet. 2009 Jul 18;374(9685):210-21
references: 19560810
references: Rheumatology (Oxford). 2011 Aug;50(8):1445-52
references: 21427177
references: Pharmacol Ther. 2008 Feb;117(2):244-79
references: 18155297
references: Curr Opin Rheumatol. 2012 May;24(3):306-11
references: 22388644
references: Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S22-7
references: 24129132
references: Ann Rheum Dis. 2011 Mar;70(3):404-13
references: 21292833
references: Lancet. 2013 Mar 16;381(9870):918-29
references: 23332236
references: Arthritis Rheum. 2006 Mar;54(3):711-5
references: 16508927
references: N Engl J Med. 2005 Sep 15;353(11):1114-23
references: 16162882
references: Ann Rheum Dis. 2010 Jun;69(6):976-86
references: 20447957
references: Arthritis Rheum. 2005 Apr;52(4):1020-30
references: 15818697